Clinical trial
CI-994 in Treating Patients With Advanced Myeloma
NCT00005624 · H. Lee Moffitt Cancer Center and Research Institute, Other · Completed
Key facts
| NCT number | NCT00005624 |
|---|---|
| Title | CI-994 in Treating Patients With Advanced Myeloma |
| Official title | A Multicenter Phase 2 Study of Oral N-Acetyl Dinaline (CI-994) in the Treatment of Patients With Advanced Myeloma |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Parke-Davis Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CI-994 |
| Enrollment | 6 |
| Start date | Aug 1, 1997 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Jul 26, 2004 |
| Last update posted | Sep 25, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: